A prospective study of the prevalence of heparin-induced antibodies and other associated thromboembolic risk factors in pediatric patients undergoing hemodialysis

American Journal of Hematology

Volumn 81, Issue 5, 2006, Pages 328-334

  Skouri, Hadef ^a   Gandouz, Raoudha ^a   Abroug, Saoussen ^a   Kraiem, Imen ^a   Euch, Henda ^b   Gargouri, Jalel ^b   Harbi, Abdelaziz ^a  

^a SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^b UNIVERSITY OF SFAX   (Tunisia)

Author keywords

Antiphospholipids; Coagulation; Hemodialysis; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; CARDIOLIPIN ANTIBODY; FIBRINOGEN; HEPARIN; HEPARIN ANTIBODY; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; THROMBOCYTE ANTIBODY; THROMBOCYTE FACTOR 4; THROMBOCYTE FACTOR 4 ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY PRODUCTION; ARTICLE; BIOASSAY; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS; HEPARIN INDUCED PLATELET ACTIVATION ASSAY; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; HYPERCOAGULABILITY; MALE; PATIENT; PEDIATRIC PATIENT; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

ADOLESCENT; AUTOANTIBODIES; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPARIN; HUMANS; INFANT; KIDNEY DISEASES; MALE; PLATELET AGGREGATION; PREVALENCE; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; THROMBOEMBOLISM;

EID: 33646491446     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20614     Document Type: Article

References (38)

1. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-555.
2. Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol 2001;54:272-274.
3. Deitcher SR, Carman TL. Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med 2001;6:113-119.
4. Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 1996;52:90-95.
5. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
6. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523-535.
7. LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 1999;189:73-79.
8. Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003;16:54-60.
9. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-385.
10. Chong BH, Eisbacher M. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin Hematol 1998;35(suppl 5):3-8.
11. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg506→Gln mutation. Blood Coagul Fibrinolys 1995;6:245-248.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
13. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190.
14. Greinacher A, Zinn S, Wizemann, Birk UW. Heparin-induced antibodies as risk factor for thrombosis and haemorrhage in patients undergoing chronic haemodialysis (Letter). Lancet 1996;348:764.
15. Sitter T, Spannagl M, Banas B, Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 1998;79:245-246.
16. Luzzatto G, Bertoli M, Cella G, Fabris F, Zaia B, Girolami A. Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 1998;89:115-122.
17. Boon DM, van Vliet HH, Zietse R, Kappers-Klunne MC. The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 1996;76:480.
18. O'Shea SI, Sands JJ, Nudo SA, Ortel TL. Frequency of anti-heparin- platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 2002;69:72-73.
19. Cines DB, Kaywin P, Bina M, Tomaski A, Schreiber AD. Heparin-associated thrombocytopenia. N Engl J Med 1980;303:788-795.
20. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-1246.
21. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
22. Matsuo T, Matuo M, Wanaka K, Sakai R. Heparin re-exposure after heparin-induced thrombocytopenia in a chronic hemodialysis patient. Clin Lab Haematol 2003;25:333-334.
23. Neuhaus TJ, Goetschel P, Schmugge M, Leumann E. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaproid. Pediatr Nephrol 2000;14:713-716.
24. Igaki N, Matsuda T, Yatani H, Kawaguchi T, Kida A, Yanase K, Moriguchi R, Sakai M, Tamada F, Goto T. Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient. Clin Exp Nephrol 2003;7:306-310.
25. Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996;28:82-85.
26. Smits JHM, van der Linden J, Blankestijn PJ, Rabelink TJ. Coagulation and haemodialysis access thrombosis. Nephrol Dial Transplant 2000;15:1755-1760.
27. Vaidya S, Sellers R, Kimball P, Shanahan T, Gitomer J, Gugliuzza K, Fish JC. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation 2000;69:1348-1352.
28. Brunet P, Aillaud MF, San Marco M, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995;48:794-800.
29. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 1999;51:116-121.
30. Erdem Y, Haznedaroglu IC, Celik I, Yalcin AU, Yasavul U, Turgan C, Caglar S. Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant 1996;11:1299-1305.
31. Shlipak MG, Freid LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
32. Song I, Yang W, Kim S, Lee J, Kwon T, Park J. Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Nephrol Dial Transplant 1999;14:137-141.
33. Lai KN, Yin JA, Yuen PM, Li PK. Protein C, protein S, antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis. Nephron 1990;56:271-276.
34. Lai KN, Yin JA, Yuen PM, Li PK. Effect of hemodialysis on protein C, protein S, and antithrombin III levels. Am J Kidney Dis 1991;17:38-42.
35. Malyszko J, Malyszko JS, Hryszko T, Pawlak K, Mysliwiec M. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients. Am J Nephrol 2004;24:624-629.
36. Kunz K, Petitjean P, Lisri M, Chantrel F, Koehl C, Wiesel ML, Cazenave JP, Moulin B, Hannedouche TP. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant 1999;14:1934-1942.
37. Mureebe L, Coats RD, Silliman WR, Shuster TA, Nichols WK, Silver D. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery 2004;136:848-853.
38. O'Shea SI, Lawson JH, Reddan D, Murphy M, Ortel TL. Hypercoagulable states and antithrombotic strategies in reccurent vascular access site thrombosis. J Vasc Surg 2003;38:541-548.